Navigation Links
QED A350 Saliva Alcohol Test

ProductsQED A350 Saliva Alcohol Test
Company STC Technologies Inc.
Item QED A350 Saliva Alcohol Test
Features 
  • 0.98 correlation to blood tests
  • better quality assurance indicator - QASpot
    • Description The A350 test is used for POC testing in hospital emergency departments, replacing the need to draw blood for alcohol testing. Each hash mark is 0.02% or 20 mg/dL.
    Info 

    Related medicine products :

    1. Donna® Saliva Ovulation Tester
    2. QED A150 Saliva Alcohol Test
    3. QED® A150 Saliva Alcohol Test
    4. Cortisol (Saliva)
    5. Cortisol, Saliva
    6. IgA, Saliva
    7. Immunoglobulin A, Saliva
    8. Alcoholic Giemsa Stain
    9. Ammonia/Alcohol Control
    10. Isopropyl Alcohol Liquid Pouch
    11. Acetone Alcohol Saturated Swabsticks
    Other Medicine News:Health News:Keith Denner Extends Current Technology's Chairman and CEO Options 2Health News:Keith Denner Extends Current Technology's Chairman and CEO Options 3Health News:Methodist Healthcare - Memphis Hospitals Announces Termination of Tender Offers 2Health News:Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors 2Health News:Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors 3Health News:Abaxis to Present at the SunTrust Robinson Humphrey's 37th Annual Institutional Unconference 2Health News:Cardinal Health Awards $1 Million to Fund Patient Safety Initiatives 2Health News:Cardinal Health Awards $1 Million to Fund Patient Safety Initiatives 3Health News:Cardinal Health Awards $1 Million to Fund Patient Safety Initiatives 4Health News:Cardinal Health Awards $1 Million to Fund Patient Safety Initiatives 5Health News:Cardinal Health Awards $1 Million to Fund Patient Safety Initiatives 6Health News:Just like penguins and other primates, people trade sex for resources 2
    Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 1VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 2VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 3VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 4Colorectal cancer 9090 1Genetically engineered mice yield clues to knocking out cancer 9086 1Genetically engineered mice yield clues to knocking out cancer 9086 2